背景:高压氧(HBO2)治疗在一系列医疗专业中用于各种应用,特别是在缺氧和炎症是重要因素的地方。由于HBO2的缺氧缓解和抗炎作用,HBO2可能对目前尚未获得海底和高压医学学会(UHMS)批准的新适应症有用。确定HBO2的这些新应用是困难的,因为各个中心可能只治疗少数病例,而不能一致地跟踪结果。基于网络的国际高压氧治疗多中心注册中心获取高压氧(HBO2)治疗患者的前瞻性结果数据。然后,这些数据可用于确定HBO2的新潜在应用,这与一系列医学专业相关。
目的:尽管高压医学已经确立了适应症,新的不断涌现。这项注册研究的一个目的是确定HBO2已用于当前UHMS批准的适应症之外的条件的情况,并提供它们的结果数据。
方法:这是一项基于Web的描述性研究,多中心,国际,用HBO2治疗的患者登记。中心同意收集使用标准结果测量治疗的所有患者的数据,并将来自各个中心的未识别数据发送到中央注册表。美国的HBO2治疗计划,英国,澳大利亚参与。人口统计,结果,并发症,和治疗数据,包括治疗前和治疗后的生活质量问卷(EQ-5D-5L)是针对接受HBO2治疗的个体收集的。
结果:在9726个患者条目中,378名患者接受了45种新兴适应症的治疗。COVID(PASC)急性后遗症(149/37840%),溃疡性结肠炎(47/37812.4%),和克罗恩病(40/37811%),占总病例的62%。钙中毒(20/3785.3%),冻伤(18/3784.8%),外周血管疾病相关伤口(12/3783.2%)占13.2%。PASC患者报告了神经行为症状量表的显着改善(NSI前30.6,NSI后14.4,p<0.001)。克罗恩病患者报告生活质量显著改善(EQ-5Dpre53.8,post68.8),5例报告瘘管闭合。溃疡性结肠炎患者表现出强烈的改善生活质量的趋势,并且在检查频率的肠问卷中报告的较低得分较低,血,疼痛,和紧迫性。钙敏感性和动脉溃疡患者的子集也报告了改善。
结论:HBO2因其缓解缺氧和抗炎作用而被广泛用于各种医学专业。结果显示,患者报告的炎症性肠病和PASC结局有统计学意义的改善。HBO2也被用于冻伤,坏疽性脓皮病,翼状胬肉,尿道下裂修复,和面部填充程序。其他适应症显示出改善的证据,并且所有适应症的病例系列在注册表中都在增加。
背景:Derr1-10.2196/18857。
■RR2-10.2196/18857。
Hyperbaric oxygen (HBO2) treatment is used across a range of medical specialties for a variety of applications, particularly where hypoxia and inflammation are important contributors. Because of its hypoxia-relieving and anti-inflammatory effects HBO2 may be useful for new indications not currently approved by the Undersea and Hyperbaric Medical Society. Identifying these new applications for HBO2 is difficult because individual centers may only treat a few cases and not track the outcomes consistently. The web-based International Multicenter Registry for Hyperbaric Oxygen Therapy captures prospective outcome data for patients treated with HBO2 therapy. These data can then be used to identify new potential applications for HBO2, which has relevance for a range of medical specialties.
Although hyperbaric medicine has established indications, new ones continue to emerge. One objective of this registry
study was to identify cases where HBO2 has been used for conditions falling outside of current Undersea and Hyperbaric Medical Society-approved indications and present outcome data for them.
This descriptive
study used data from a web-based, multicenter, international registry of patients treated with HBO2. Participating centers agree to collect data on all patients treated using standard outcome measures, and individual centers send deidentified data to the central registry. HBO2 treatment programs in the United States, the United Kingdom, and Australia participate. Demographic, outcome, complication, and treatment data, including pre- and posttreatment quality of life questionnaires (EQ-5D-5L) were collected for individuals referred for HBO2 treatment.
Out of 9726 patient entries, 378 (3.89%) individuals were treated for 45 emerging indications. Post-COVID-19 condition (PCC; also known as postacute sequelae of COVID-19; 149/378, 39.4%), ulcerative colitis (47/378, 12.4%), and Crohn disease (40/378, 10.6%) accounted for 62.4% (n=236) of the total cases.
Calciphylaxis (20/378, 5.3%), frostbite (18/378, 4.8%), and peripheral vascular disease-related wounds (12/378, 3.2%) accounted for a further 13.2% (n=50). Patients with PCC reported significant improvement on the Neurobehavioral Symptom Inventory (NSI score: pretreatment=30.6; posttreatment=14.4; P<.001). Patients with Crohn disease reported significantly improved quality of life (EQ-5D score: pretreatment=53.8; posttreatment=68.8), and 5 (13%) reported closing a fistula. Patients with ulcerative colitis and complete pre- and post-HBO2 data reported improved quality of life and lower scores on a bowel questionnaire examining frequency, blood, pain, and urgency. A subset of patients with
calciphylaxis and arterial ulcers also reported improvement.
HBO2 is being used for a wide range of possible applications across various medical specialties for its hypoxia-relieving and anti-inflammatory effects. Results show statistically significant improvements in patient-reported outcomes for inflammatory bowel disease and PCC. HBO2 is also being used for frostbite, pyoderma gangrenosum, pterygium, hypospadias repair, and facial filler procedures. Other indications show evidence for improvement, and the case series for all indications is growing in the registry.
RR2-10.2196/18857.